Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival

作者：Krisl Jill C^*; Alloway Rita R; Shield Adele Rike; Govil Amit; Mogilishetty Gautham; Cardi Michael; Diwan Tayyab; Abu Jawdeh Bassam G; Girnita Alin; Witte David; Woodle E Steve

来源：Transplantation, 2015, 99(10): 2167-2173.

DOI：10.1097/TP.0000000000000706

Background. Classification of acute rejection (AR) based on etiology and timing may provide a means for enhancing therapeutic results and allograft survival. This study evaluated graft and patient survival after the first AR episodes among kidney transplant recipients with an early or late antibody-mediated rejection (AMR), acute cellular rejection (ACR) or mixed AR (MAR). Methods. A prospective institutional review board-approved database was queried to identify biopsy-proven first AR episodes occurring from January 2005 to October 2012. The ACR was defined by Banff criteria; borderline AR was excluded. The AMR was defined as 3 of 4 criteria: renal dysfunction, donor specific antibody, C4d positivity on biopsy, and histological changes. The MAR met criteria for both ACR and AMR. Early AR occurred within six months post-transplant. AR episodes were then assigned to 1 of the 6 categories-early AMR, early ACR, early MAR, late AMR, late ACR, and late MAR. Results. One hundred eighty-two kidney transplant recipients identified with a first AR episode. Mean follow-up was 773 days (+/- 715 days). No difference was observed in patient survival. Death-censored graft survival was 84%. Death-censored graft loss was higher with late versus early AMR (P = 0.01) and late versus early ACR (P = 0.03), but not late versus early MAR (P = 0.3). Conclusions. The AR type demonstrated a hierarchy for graft survival with ACR better than MAR better than AMR, which persisted for both early and late AR. Improvement in long-term results of AR may require development of specific treatment for individual AR types.

• 出版日期2015-10